AZN Stock Recent News
AZN LATEST HEADLINES
The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—hitting all-time highs even as the broader market indices attempt to regain their footing.
AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the £450 million forecast to be spent to facilitate the site development, the former Tory government had promised to contribute £65 million.
The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.
AstraZeneca PLC (LSE:AZN) has become the first UK-listed company to surpass a £200 billion stock market valuation after shares gained on Tuesday. Shares ticked up 1.2% to 12,928p throughout the day, leaving the pharmaceutical giant with a £200.02 billion valuation.
Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertility Assets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit" or the “Company”), today announced that the Company has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, a myeloperoxidase inhibitor (MPO).
AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.
AstraZeneca's CEO has a vision for the weight loss drugs market. There probably won't be one medicine that's useful in every niche.